Cynata receives acceptance from IP Australia from Cymerus

Company News

by Anna Napoli

Cynata Therapeutics (ASX:CYP) has received the green light from IP Australia for its Cymerus technology.

The patent application is among the IP licensed exclusively from the Wisconsin Alumni Research Foundation to Cynata.

Cynata has previously been granted a patent in the US by the US Patent and Trademark Office covering the same technology.

CEO DR Ross Macdonald says Cynata's robust intellectual property around the Cymerus therapeutic stem cell platform technology continues to expand and strengthen.

Shares in Cynata (ASX:CYP) last traded at $1.30

Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.